anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

191,461-191,520 of 319,975

filter-aware
09
The slide uses a process flow diagram to explain the drug discovery pipeline from patient cohort to manufacturing.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
10
The slide uses a process flow diagram to illustrate the transformation of biological targets into optimized drug candidates.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
11
The slide uses a process-flow visual to contrast discovery vs. optimization.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
12
The slide features the company logo and a stylized 'a' graphic.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
13
The slide highlights a specific Nature Biomedical Engineering paper as validation of the company's core technology approach.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
14
The slide uses a process flow diagram to show the transition from parental mAb to optimized mAb via AI.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
15
The slide outlines a technical methodology for biological data generation.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
16
The slide includes a small schematic icon representing the scatter plot and a callout box emphasizing the necessity of high-quality data for AI training.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
17
The table outlines the experimental design for antibody optimization models, specifically highlighting the differences in sampling strategies and mutational loads.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
18
The slide explains the methodology behind the dataset used for AI lead optimization, specifically focusing on the combinatorial space of amino acid mutations.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
19
Includes scatter plots showing correlation and a bar chart comparing model performance metrics against experimental replicates.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
20
The chart shows density vs -log10Kd, comparing design vs validation vs measured trastuzumab.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
21
The slide highlights the methodology of sampling sequence space and validating predictive models against measured binding affinity.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
22
The chart compares High vs Low Fidelity models with and without pretraining across different training data sizes.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
23
The slide shows scatter plots for quadruple and quintuple mutants and a summary bar chart for performance metrics.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
24
The slide uses a combination of diagrams and a summary box to explain the methodology of using AI to predict antibody naturalness.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
25
The slide uses box plots and bar charts to show statistical correlation between naturalness and clinical/developability outcomes.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
26
The slide uses box plots and density plots to demonstrate that higher naturalness correlates with better expression and lower mutational burden.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
27
The charts show the progression of antibody variants over generations, highlighting the improvement in ACE score and naturalness metrics.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
28
The slide uses a process diagram to illustrate the 'in silico' lead optimization workflow.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
29
The slide uses a process flow diagram to show the integration of AI in drug development.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
30
The slide uses a lightbulb icon as a metaphor for innovation.Absci | Investor Presentation Deck | 30 slides · Absci
Pitch deck Investor relations 1 hit
01
Slide 1
Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
02
Includes a specific disclosure regarding Dr. Harvey Levy's role as a Principal Investigator and Consultant.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
03
Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
04
Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
05
The slide uses a Gantt-style bar chart to represent clinical trial phases for each drug program.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
06
Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
07
The slide uses a hierarchical diagram to map the clinical manifestations of the disease.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
08
The diagram illustrates the metabolic pathway and the specific block at the Cystathionine beta-synthase step.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
09
The table contrasts clinical outcomes (Hcy levels, lens dislocation, IQ, thrombosis, mortality) between two patient cohorts.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
10
Includes a citation of the specific clinical guidelines paper.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
11
Includes historical context of diagnostic methods (pre-NBS era).Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
12
The slide uses a table to show symptom overlap (+) and absence (-) between two conditions, accompanied by a visual comparison of patients.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
13
The slide highlights the clinical consequences of missing HCU in newborn screening (NBS).Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
14
The slide displays various medical nutrition products used for HCU management.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
15
Includes a clinical photograph of two patients, likely illustrating physical manifestations or growth issues associated with the condition.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
16
Case study format used to illustrate the consequences of poor disease management.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
17
The slide uses a list-based approach to describe the disease burden, paired with a visual column of key clinical manifestations.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
18
The slide uses a simple problem-solution structure, identifying the clinical gap and the resulting need.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
19
Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
20
Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
21
The slide uses a pie chart to show patient segmentation by B6 responsiveness and a timeline/number-line to show age of diagnosis, followed by key metrics on complication rates.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
22
Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
23
The slide uses a process flow diagram to show the metabolic block (CBS deficiency) and the therapeutic intervention point.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
24
The slide uses a biological process diagram to contrast normal intracellular metabolism with the therapeutic effect of the drug in the plasma.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
25
The slide uses a process flow diagram to represent clinical trial cohorts and study design.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
26
Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
27
Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slidesAeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
28
This is a standard corporate cover slide featuring the company logo and address.Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides · Aeglea BioTherapeutics
Conference presentation Investor relations 1 hit
01
Slide 1
Albireo Pharma | Results Presentation Deck | 18 slidesAlbireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations 1 hit
02
Albireo Pharma | Results Presentation Deck | 18 slidesAlbireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations 1 hit
03
Albireo Pharma | Results Presentation Deck | 18 slidesAlbireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations 1 hit
04
The slide uses a stylized logo for the ASSERT study.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations 1 hit
05
The chart uses stacked bars to represent cumulative patient population growth associated with clinical trial programs (PEDFIC, ASSERT, BOLD).Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations 1 hit
06
Includes a photo of a child with medical equipment to humanize the disease impact.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · Problem1 hit
07
The slide outlines a standard randomized controlled trial (RCT) design for a pharmaceutical study.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · Agitate1 hit
08
The slide includes a footer note regarding patient completion rates.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · Agitate1 hit
09
Clinical trial data showing efficacy of Odevixibat (Bylvay) vs Placebo.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
10
The chart displays LS Mean (95% CI) with p-value significance markers.Albireo Pharma | Results Presentation Deck | 18 slides · Albireo Pharma
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit